Nutritional Supplement Ferric Citrate CAS 2338-05-8

Unit Price: USD 1.0000 / Gram
Payment Type: T/T
Incoterm: CIF
Min. Order: 1 Gram
Delivery Time: 15 Days

Basic Info

Model No.: 2338-05-8

Additional Info

Packaging: As Quantity

Productivity: As Order


Transportation: Air

Place of Origin: CHINA

Supply Ability: IN STOCK

Product Description

     Ferric citrate monohydrate CAS Number is 2338-05-8, also known as ferric citrate, is a chemical product that has been used for many years. It is a structurally indeterminate complex. According to the literature, the method for synthesizing Ferric citrate monohydrate is to use citric acid and ferric hydroxide as raw materials, add citric acid to iron hydroxide, heat at a temperature lower than 60℃, evaporate to a slurry, and coat it on a glass plate. Above, dry at low temperature until a small piece is formed, and peeling is obtained. This conventional Ferric citrate monohydrate CAS Number 2338-05-8 can only be called crude iron citrate, which is purple-brown and thin scaly. The method of preparing iron citrate used for many years should be said to be very random. The final product is mainly composed of iron citrate. There are no clear requirements for the various conditions of the preparation process and the performance of the final product, resulting in the product being soluble in water but not easily dissolved. Later, some researchers adjusted the bulk density of the solid finished iron citrate and made solid iron citrate of different densities. The obtained product has extremely fine voids inside and has a large surface area, so it is easily dissolved by water. It solves the problem that the medicinal solubility of iron citrate is small.
The preparation method of the pharmaceutical grade iron citrate is prepared by mixing iron hydroxide as a starting material with 1.05 equivalent of citric acid containing one crystal water, and then adding purified water, and then reacting in a water bath of 60-70℃, The reaction was carried out for about 48 to 2 hours, and centrifuged at 4000 rpm to remove suspended particles. The supernatant was heated and evaporated at 60℃ to remove water, and then spread on a flat plate and dried to obtain crude granules. The obtained crude granules were immersed in 95% ethanol at room temperature or lower for 2 hours, and the residual citric acid was dissolved therein. Filtration and ethanol elution gave pharmaceutical grade iron citrate.
At present, iron citrate CAS Number 2338-05-8 is mainly a food additive for iron supplementation or a nutritional supplement. For example, it can be added to biscuits, calcium milk powder and wheat flour, and India is also used for salt. In addition, there are reports on the treatment of hyperphosphatemia in patients with chronic renal failure. Iron citrate has been reported as a new phosphorus-binding agent for hemodialysis patients with chronic renal failure. It can be taken at the same time as food. The phosphate in the gastrointestinal tract reduces the absorption of phosphate in the gastrointestinal tract, thereby reducing hyperphosphatemia in patients with chronic renal failure. Because of the cardiovascular calcification in patients with chronic kidney disease, there is a view that hyperphosphatemia is an influencing factor of cardiovascular calcification in patients with ESRD (end-stage renal failure), and hyperphosphatemia is involved in vascular ectopic calcification of ESRD. However, the blood phosphorus and blood calcium of ESRD patients with partial vascular calcification are still normal. In addition, vascular calcification associated with atherosclerosis is not directly related to human blood phosphorus levels. Therefore, cardiovascular calcification of chronic renal failure is a multi-pathogenic, multi-pathway, very complex process involving multiple molecules, and the effect of blood phosphorus levels on calcification is unknown.
It has been found that iron citrate can effectively prevent arterial calcification in rats caused by vitamin D3 and nicotine, which proves that iron citrate can effectively inhibit cardiovascular ectopic calcification by intervening in the process of soft tissue calcification, and it is possible Reverse the occurrence of ectopic calcification.

Thera. Category: Nutritional Supplement

Cas No.: 2338-05-8

Synonyms:Iron(III) citrate tribasic monohydrate,Ferric citrate monohydrate;IRON(lll) CITRATE, hydrate, tech-95;FERRIC CITRATE NHYD;Iron citrate tetrahydrate;Ferric Citrate, Powder;Iron(Ⅲ) Citrate n-Hydrate;2,3-propanetricarboxylicacid,2-hydroxy-ironsalt;IRON (III) CITRATE, GREEN

MF:  C6H5FeO7



Assay: ≥99%

Packing:Export worthy packing

Material Safety Data Sheet:Available on request


Active Pharmaceutical Ingredients> Cas 90098-04-7,Rebamipide Named In Mucosta With GMP Standard
Active Pharmaceutical Ingredients> Functional Dyspepsia Treatment Acotiamide Hydrochloride Trihydrate CAS 773092-05-0
Active Pharmaceutical Ingredients> Acotiamide Hydrochloride For Gastric Motility Improvement CAS 185104-11-4
Contract Manufacturing> ASCORBYL GLUCOSIDE Used for Comesitc Additive CAS 129499-78-1
Pharmaceutical Intermediates> Anti-Ulcerative> 2-Aminothiazole-4-ethylformate For Making Acotiamide Cas 5398-36-7
Pharmaceutical Intermediates> Anti-Ulcerative> Acotiamide INT CAS NUMBER 185105-98-0
Pharmaceutical Intermediates> Anti-Cardiovascular> Azilsartan Used for Hypertension Treatment CAS 147403-03-0
Pharmaceutical Intermediates> Anti-Diabetes> Sitagliptin Phosphate Monohydrate Treated for Type 2 diabetes CAS Number 654671-77-9
Pharmaceutical Intermediates> Anti-Ulcerative> Cas 132210-24-3, 2-Amino-3-(1,2-dihydro-2-oxo-quinoline-4-yl)Propanoic acid Hydrochloride For Rebamipide
Pharmaceutical Intermediates> Anti-Ulcerative> Cas 1068-90-2 White Crystalline Powder Diethyl Acetamidomalonate For Rebamipide(DAAM)
Active Pharmaceutical Ingredients> 6027-23-2, Hordenine HCL Powder
Pharmaceutical Intermediates> Anti-Ulcerative> Cas 4876-10-2,4-Bromomethyl-2(1H)-quinolinone (BMQ) For Rebamipide/ Mucosta
Pharmaceutical Intermediates> Anti-Respiratory> CAS 2338-18-3, 2-Aminoindan hydrochloride For Making Indacaterol
Pharmaceutical Intermediates> Anti-Respiratory> CAS 312753-53-0/ 5,6-Diethyl-2,3-dihydro-1H-inden-2-amine hydrochloride Used for Indacaterol
Pharmaceutical Intermediates> Anti-Respiratory> 312753-53-0, Indacaterol Intermediate
Pharmaceutical Intermediates> Anti-Respiratory> 100331-89-3, Indacaterol Intermediate

© 2019 CHINA WAY. All Rights Reserved.  Taizhou Volsen Chemical Co., Ltd.,  Inc.   All rights reserved. site map.  sitemap.html